By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Proclara Biosciences (Formerly known as NeuroPhage) 

222 Third Street
Suite 3120
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-714-5468 Fax: 617-714-5469




Company News
Proclara Awarded Part The Cloud Grant From Alzheimer’s Association To Support Development Of NPT088 For Alzheimer’s Disease 11/18/2016 7:43:03 AM
Proclara Announces Newly Issued U.S. Patents For Its Core Technology Targeting Protein Misfolding Disorders 11/16/2016 8:30:22 AM
Proclara Announces Initiation Of Phase Ib Clinical Trial Of NPT088 For Alzheimer’s Disease 9/7/2016 11:39:39 AM
NeuroPhage Transforms Into Proclara, Bags $47 Million and and Launches Phase Ib Alzheimer’s Trial 9/7/2016 5:45:37 AM
NeuroPhage Pharmaceuticals, Inc.'s NPT088 Universally Targets Misfolded Proteins In Preclinical Studies Highlighted In Oral Session At The Alzheimer's Association International Conference 7/20/2015 8:01:14 AM
NeuroPhage Pharmaceuticals, Inc. To Be Featured In Oral Session At The 2015 Alzheimer's Association International Conference 7/13/2015 7:35:01 AM
NeuroPhage Pharmaceuticals, Inc. To Participate On Neuroscience Drug Development Panel At Massbio Annual Meeting March 27, 2015 3/20/2015 1:45:27 PM
NeuroPhage Pharmaceuticals, Inc. To Present At 12th International Conference On Alzheimer's & Parkinson's Diseases 3/17/2015 10:14:54 AM
NeuroPhage Pharmaceuticals, Inc. Expands Series D Financing To $27 Million 1/14/2015 7:15:27 AM
NeuroPhage Pharmaceuticals, Inc.'s GAIM Technology Chosen As 'Top Project To Watch' For The Therapeutic Area Partnerships Conference 11/14/2014 8:07:58 AM